{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:09:59Z","timestamp":1780106999022,"version":"3.54.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2410-H-037-002-MY3"],"award-info":[{"award-number":["111-2410-H-037-002-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 114-2410-H-037-009-SS3"],"award-info":[{"award-number":["NSTC 114-2410-H-037-009-SS3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.diabres.2026.113186","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:52:19Z","timestamp":1771865539000},"page":"113186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study"],"prefix":"10.1016","volume":"234","author":[{"given":"Hsiao-Yuan","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-0190","authenticated-orcid":false,"given":"Hon-Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.diabres.2026.113186_b0005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2024.27402","article-title":"Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis","volume":"333","author":"Hanlon","year":"2025","journal-title":"J Am Med Assoc"},{"issue":"10403","key":"10.1016\/j.diabres.2026.113186_b0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.diabres.2026.113186_b0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2026.113186_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113186_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111871","article-title":"A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U\/mL in insulin-naive people with type 2 diabetes with\/without prior use of glucagon-like peptide-1 receptor agonist therapy","volume":"217","author":"Cheng","year":"2024","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113186_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2025.3599","article-title":"Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: the OASIS 2 randomized clinical trial","author":"Kadowaki","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113186_b0035","first-page":"e65","article-title":"Effect of oral semaglutide versus comparators on multiple cardiometabolic risk factor control in adults with type 2 diabetes","volume":"48","author":"Aroda","year":"2025","journal-title":"Diab Care"},{"issue":"9","key":"10.1016\/j.diabres.2026.113186_b0040","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.diabres.2026.113186_b0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2026.113186_b0050","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.clinthera.2021.08.015","article-title":"Lifetime cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics","volume":"43","author":"Risebrough","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2026.113186_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083039","article-title":"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis","volume":"390","author":"Nong","year":"2025","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.diabres.2026.113186_b0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","article-title":"Economic burden of cardiovascular disease in type 2 diabetes: a systematic review","volume":"21","author":"Einarson","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2026.113186_b0065","unstructured":"National Health Insurance (NHI) Drug Item Online Query Service, National Health Insurance Administration (NHIA), Ministry of Health and Welfare, Taiwan. Available from https:\/\/info.nhi.gov.tw\/INAE3000\/INAE3000S01 Accessed 1 August 2025."},{"issue":"7","key":"10.1016\/j.diabres.2026.113186_b0070","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s11136-021-02808-2","article-title":"Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes","volume":"30","author":"Matza","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.diabres.2026.113186_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1226778","article-title":"Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China","volume":"14","author":"Feng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113186_b0080","unstructured":"Directorate General of Budget, Accounting and Statistics, Executive Yuan, R.O.C. (Taiwan). Macro Database. https:\/\/nstatdb.dgbas.gov.tw\/dgbasall\/webMain.aspx?k=engmain. Accessed 25 February 2025."},{"key":"10.1016\/j.diabres.2026.113186_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111928","article-title":"Tuscany study group- italian diabetologists association AMD real world effectiveness of oral semaglutide: focus on patients with type 2 diabetes older than 75 years","volume":"218","author":"Baronti","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.diabres.2026.113186_b0090","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1111\/dom.16314","article-title":"Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: a real-world retrospective study","volume":"27","author":"Costa","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"10.1016\/j.diabres.2026.113186_b0095","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113186_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110625","article-title":"Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: a model-based cost-effectiveness analysis using real-world data","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"15","key":"10.1016\/j.diabres.2026.113186_b0105","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jama.2023.16096","article-title":"Million hearts cardiovascular disease risk reduction model","volume":"330","author":"Tajeu","year":"2023","journal-title":"J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.diabres.2026.113186_b0110","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1161\/CIR.0000000000001355","article-title":"Use of risk assessment to guide decision-making for blood pressure management in the primary prevention of cardiovascular disease: a scientific statement from the American heart association and American college of cardiology","volume":"152","author":"Khan","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2026.113186_b0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13098-022-00801-4","article-title":"The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal","volume":"14","author":"Malkin","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"10.1016\/j.diabres.2026.113186_b0120","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/13696998.2020.1722678","article-title":"Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis","volume":"23","author":"Hansen","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.diabres.2026.113186_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110881","article-title":"The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide","volume":"203","author":"Kurtzhals","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113186_b0130","unstructured":"Annual reports in the Taiwanese Association of Diabetes Educators (TADE). https:\/\/www.tade.org.tw\/en\/ Accessed 17 October 2024."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:45:28Z","timestamp":1780105528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0168822726001051"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113186","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113186"}}